Post job

BeiGene's revenue is $3.8 billion.

What is BeiGene's revenue?

BeiGene's annual revenue is $3.8B. Zippia's data science team found the following key financial metrics about BeiGene after extensive research and analysis.
  • BeiGene's revenue growth from 2015 to 2024 is 43,119.61%.
  • BeiGene has 5,300 employees, and the revenue per employee ratio is $718,913.
  • BeiGene's peak quarterly revenue was $1.1B in 2024(q4).
  • BeiGene peak revenue was $3.8B in 2024.
  • BeiGene annual revenue for 2023 was 2.5B, 73.65% growth from 2022.
  • BeiGene annual revenue for 2024 was 3.8B, 54.96% growth from 2023.

On this page

Most recent quarter revenue
$1.1B (Q4'2024)
Company most recent quarter revenue
Peak revenue
$3.8B (2024)
Company peak revenue
Revenue / employee
$718,913
Company revenue / employee

Zippia finds jobs where you're a top candidate and applies on your behalf.

Floating question marks illustration
Most recent quarter revenue
$1.1B (Q4'2024)
Company most recent quarter revenue
Peak revenue
$3.8B (2024)
Company peak revenue
Revenue / employee
$718,913
Company revenue / employee

BeiGene historical revenue

BeiGene's peak revenue was $3.8B in 2024. The peak quarterly revenue was $1.1B in 2024(q4).

BeiGene's revenue increased from $8.8m in 2015 to $3.8B currently. That's a 43,119.61% change in annual revenue.

BeiGene annual revenue

$4B
$3B
$2B
$2B
$762M
$0
2019
2020
2021
2022
2023
2024

BeiGene annual revenue over time

Fiscal year / yearBeiGene revenue
2015$8.8M
2016$1.1M
2017$238.4M
2018$198.2M
2019$428.2M
2020$308.9M
2021$1.2B
2022$1.4B
2023$2.5B
2024$3.8B

Rate BeiGene's financial transparency

Zippia waving zebra

BeiGene annual growth

BeiGene saw the greatest revenue growth in 2017, when revenue increased by 22,179.16%.

BeiGene had the lowest revenue growth in 2016, when revenue changed by -87.86%.

BeiGene annual growth rate over time

YearBeiGene growth
2016
-88%
2017
22179%
2018
-17%
2019
116%
2020
-28%
2021
281%
2022
20%
2023
74%
2024
55%

BeiGene quarterly revenue over time

  • Q1
  • Q2
  • Q3
  • Q4
$1B
$902M
$677M
$451M
$226M
$0
2020
2021
2022
2023
2024

BeiGene quarterly growth rate over time

YearQ1Q2Q3Q4
2015---$4.7M
2016$677,000$393,000--
2017--$220.2M$18.2M
2018$32.5M$52.8M$54.2M$58.7M
2019$77.8M$243.3M$50.1M$56.9M
2020$52.1M$65.6M$91.1M$100.1M
2021$605.9M$150.0M$206.4M$214.0M
2022$306.6M$341.6M$387.6M$380.1M
2023$447.8M$595.3M$781.3M$634.4M
2024$751.7M$929.2M$1.0B$1.1B

BeiGene jobs nearby

Do you work at BeiGene?

Did BeiGene meet its revenue projections?

BeiGene financial information

CEOJohn V. Oyler
IndustryPharmaceuticals, Biotechnology & Life Sciences
Company TypePublic
Employees Number5,300
Date Founded2010
HeadquartersCambridge, Massachusetts
Number of Locations1
Revenue$3.8B
Net Income-$2,003,815,000
Gross Proft$3.2B (2024)
EBITDA($1.4B) (2021)
Tax Rate-0.2%
Total Assets$6,379,290,000
TickerBGNE

BeiGene jobs you might like

BeiGene revenue FAQs

Search for jobs

Zippia gives an in-depth look into the details of BeiGene, including salaries, political affiliations, employee data, and more, in order to inform job seekers about BeiGene. The employee data is based on information from people who have self-reported their past or current employments at BeiGene. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by BeiGene. The data presented on this page does not represent the view of BeiGene and its employees or that of Zippia.

BeiGene may also be known as or be related to BEIGENE, LTD, BeiGene, BeiGene Ltd and Beigene.